ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Long-Term Debt
ExpreS2ion Biotech Holding AB
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Long-Term Debt
kr853k
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Long-Term Debt
kr4.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Long-Term Debt
kr1.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
100%
|
CAGR 10-Years
46%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Long-Term Debt
kr5.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
21%
|
|
|
BioArctic AB
STO:BIOA B
|
Long-Term Debt
kr28.3m
|
CAGR 3-Years
188%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Long-Term Debt?
Long-Term Debt
853k
SEK
Based on the financial report for Dec 31, 2025, ExpreS2ion Biotech Holding AB's Long-Term Debt amounts to 853k SEK.
What is ExpreS2ion Biotech Holding AB's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-31%
Over the last year, the Long-Term Debt growth was -41%. The average annual Long-Term Debt growth rates for ExpreS2ion Biotech Holding AB have been -25% over the past three years , -31% over the past five years .
